Prestige Biologics (KOSDAQ:334970) secured a contract manufacturing agreement for active pharmaceutical ingredients (APIs) following a technology transfer from an undisclosed client, according to a Friday filing with the Korea Exchange.
The deal, valued at 2.40 billion won, is valid till March 31, 2027.
Shares of Prestige Biologics fell nearly 2% in recent trade.